Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

p>

  • Top line results from the phase II trial in healthy adults with our trivalent seasonal flu vaccine candidate;
  • Preclinical results of studies with vaccine candidates against the Respiratory Syncitial Virus (RSV);
  • Commencement of operations of the joint venture with Cadila Pharmaceuticals Ltd in India; and,
  • Initiation of a Phase II clinical study of our trivalent seasonal flu vaccine in older adults.

2009 Financial Results

Revenue from operations for the first quarter ended March 31, 2009 was $0.02 million compared to $0.5 million for the same period in 2008, a net decrease of $0.4 million due to the completion of a government contract in the first quarter of 2009.

Research and development costs for the first quarter of 2009 were $4.3 million compared to $4.4 million in the first quarter of 2008. The decrease was due to a $0.2 million decrease in employee costs and a $0.1 million decrease associated with the closing of the Taft Court facility in October 2008 when the Company consolidated its operations into the Belward Campus facility. These decreases were partially offset by an increase in $0.1 million in outside testing costs associated with the continuing clinical trials, preclinical testing, process development, manufacturing and quality related programs and a $0.1 million increase in facility costs.

General and administrative costs were $2.9 million in the first quarter of 2009 as compared to $3.2 million in the first quarter of 2008. The $0.3 million decrease was due to a decrease in employee costs of $0.1 million, a decrease in facility costs associated with general and administrative functions of $0.1 million, and a decrease of $0.2 million in charges to the allowance established for two notes receivable from former directors. The Company determined that the notes receivable
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  With over 60,000 customers across the globe, ISN improves the ... hiring organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 ... Headquartered in Dallas, TX , ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a follow ... service business units, Whitehouse Laboratories is pleased to announce that it has begun construction ... Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, and ...
(Date:7/29/2015)... , July 30, 2015 According ... Market - Growth, Trends & Forecasts (2015-2020), , published by ... US$ 30.25 billion by the end of 2020, with ... accounting for more than 40% of the global market size. ... at a CAGR of 13.7% during the period of (2015-2020). ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), ... healthcare services, offering both facility-based and home-based post-acute ... the second quarter ended June 30, 2015. ... volume growth in both segments and an 11.0% ... President and Chief Executive Officer of HealthSouth. "While ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31
... 10, 2010 Ramius V&O Acquisition LLC, a subsidiary ... has sent a letter to the Board of Directors ... outlining its willingness to acquire all of Cypress, outstanding ... share.  The offer is conditioned upon Cypress commencing exclusive ...
... 10, 2010 Pfizer Inc. (NYSE: PFE ... safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the ... it is approved (the European Union, Canada and Australia). ... worldwide. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) Pfizer,s ...
... will help UK athletes reach the top of their ... the UK,s high performance sports agency, has reached an ... edge technology developed by Argento Diagnostics to improve training ... to monitor various proteins which reveal details about the ...
Cached Biology Technology:Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 2Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 3Medical science helps UK athletes reach peak performance 2Medical science helps UK athletes reach peak performance 3
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik (ICG-10, ... vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ihr ... ICG weltweit zu einem der einflussreichsten jährlichen Treffen ... dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/31/2015)... China , July 31, 2015 The 10 ... will be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th anniversary ... one of the world,s most influential annual meetings in the ... and enjoyable scientific gatherings. ICG-10 focuses on ...
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... At some point this year, after NASA,s rover Curiosity has ... infrared light at a rock or soil sample. This will ... a plume of ionized gas or plasma, which will be ... Mars rovers, however, will be able to do even more. ...
... 1, 2012 Probing the largely unexplored question of ... have discovered that by mimicking nature, a robotic fish ... Through a series of experiments, researchers from Polytechnic Institute ... of collective animal behavior, including learning how robots might ...
... Philadelphia, PA, March 1, 2012 Down syndrome (DS) ... children arising as a consequence of a chromosomal abnormality. ... of chromosome 21, instead of the usual two. It ... dysfunction that can range from mild to severe but ...
Cached Biology News:LAMIS -- a green chemistry alternative for laser spectroscopy 2LAMIS -- a green chemistry alternative for laser spectroscopy 3LAMIS -- a green chemistry alternative for laser spectroscopy 4What makes a robot fish attractive? (Hint: It's in the moves) 2Understanding and treating the cognitive dysfunction of Down syndrome and Alzheimer's disease 2
... Monitoring Kit measures adenosine triphosphate ... and a dynamic range. Based ... assay measures ATP in bacterial, ... a concentration range of 10-11 ...
... series of refrigerated cold traps offers a ... low volatility/aqueous solvents or high volatility solvents. ... vacuum concentrators/centrifugal evaporators. Also used for maintaining ... as used in electron microscopes. Can be ...
... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
Black 96 Well Plate EB, RE Bottom...
Biology Products: